PRKN and Parkinson disease: A further interesting aspect raised by omics observations derives from a challenging clinical trial recently launched with the aim to assess the treatment response of the coenzyme Q10 (a “mitochondrial enhancer”) in four PD patient subgroups genetically stratified through an omics-score predictive for their potential “mitochondrial risk burden” (i.e., homozygous or compound heterozygous Parkin/PINK1 mutation carriers, heterozygous Parkin/PINK1 mutation carriers, “omics” positive and “omics” negative patients) [39] (Table 1).